These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35973601)

  • 1. Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.
    Belouin SJ; Averill LA; Henningfield JE; Xenakis SN; Donato I; Grob CS; Berger A; Magar V; Danforth AL; Anderson BT
    Neuropharmacology; 2022 Nov; 219():109214. PubMed ID: 35973601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations.
    Wolfgang AS; Hoge CW
    Curr Psychiatry Rep; 2023 Oct; 25(10):513-532. PubMed ID: 37682446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethical considerations for psychedelic-assisted therapy in military clinical settings.
    Hoener S; Wolfgang A; Nissan D; Howe E
    J Med Ethics; 2024 Mar; 50(4):258-262. PubMed ID: 37253556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychedelic drugs-a new era in
psychiatry?
.
    Nutt D
    Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Emerging Field of Psychedelic Psychotherapy.
    Barber GS; Aaronson ST
    Curr Psychiatry Rep; 2022 Oct; 24(10):583-590. PubMed ID: 36129571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
    Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
    Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy.
    Mocanu V; Mackay L; Christie D; Argento E
    Subst Abuse Treat Prev Policy; 2022 May; 17(1):37. PubMed ID: 35568884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is needed for the roll-out of psychedelic treatments?
    Xenakis SN; Shannon SM
    Curr Opin Psychiatry; 2024 Jul; 37(4):277-281. PubMed ID: 38726805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The need for establishing best practices and gold standards in psychedelic medicine.
    Feduccia A; Agin-Liebes G; Price CM; Grinsell N; Paradise S; Rabin DM
    J Affect Disord; 2023 Jul; 332():47-54. PubMed ID: 37003433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.
    Stein CA; Penn A; Van Hope S; Dorsen CG; Mangini M
    J Midwifery Womens Health; 2022 May; 67(3):373-383. PubMed ID: 35522087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.
    Hsu TW; Tsai CK; Kao YC; Thompson T; Carvalho AF; Yang FC; Tseng PT; Hsu CW; Yu CL; Tu YK; Liang CS
    BMJ; 2024 Aug; 386():e078607. PubMed ID: 39168500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelic Drug Legislative Reform and Legalization in the US.
    Siegel JS; Daily JE; Perry DA; Nicol GE
    JAMA Psychiatry; 2023 Jan; 80(1):77-83. PubMed ID: 36477830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of psilocybin and MDMA in the treatment of mental illness.
    Gill H; Gill B; Chen-Li D; El-Halabi S; Rodrigues NB; Cha DS; Lipsitz O; Lee Y; Rosenblat JD; Majeed A; Mansur RB; Nasri F; Ho R; McIntyre RS
    Expert Rev Neurother; 2020 Dec; 20(12):1263-1273. PubMed ID: 32954860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
    Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; Yehuda R
    Curr Neuropharmacol; 2024; 22(4):636-735. PubMed ID: 38284341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelic research at a crossroads.
    Armstrong SB; Davis AK
    Science; 2024 Sep; 385(6715):1255. PubMed ID: 39298596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
    Barnett BS; Parker SE; Weleff J
    Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.